Login to Your Account

Medeor cell therapy to convert transplantation into possible cures

By Marie Powers
News Editor

Friday, April 28, 2017

Formed three years ago, privately held Medeor Therapeutics Inc. is moving its lead cellular immunotherapy candidate, MDR-101, directly into a pivotal phase III study, with its IND application cleared by the FDA along with agreement to an SPA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription